Earnings season is when investors get a progress report about the companies in their portfolio or on their watchlist. An earnings report is generally a lagging indicator. That’s because the headline ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

An academic study of the merger hopes to give insight into how attorneys general can strengthen certificate-of-need laws and the importance of having more power over sales. Other industry news focuses ...

Optomi Professional Services (OPS) is pleased to announce the appointment of Carey Luhn as the organization's Vice President of Strategic Accounts. In this role, Luhn will be responsible for creating ...

OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...

Dr Craig Koniver, a family physician in Charleston, South Carolina, said he currently has 200 patients using the same method ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.In an interview with Healio, ...

Eli Lilly has been a terrific stock to own for the past five years, thanks to its excellent clinical and regulatory progress. The company's breakthroughs are paying off. In each of the past six ...

They called it the “VIVA ZYPREXA” campaign to off label market Eli Lilly Zyprexa as a fix for unapproved usage. Zyprexa (Olanzapine) is known as an atypical antipsychotic It’s ...